Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.

about

Physiological and pathological implications of 5-hydroxymethylcytosine in diseases

P2860

Q26749375-6B1632D8-CF20-4D56-8C59-B60519263615

P2860

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.

Item

http://www.wikidata.org/entity/Q39202346

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Hematologic improvements in a ...... ient treated with azacitidine.

@en

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis

@nl

type

Item

label

Hematologic improvements in a ...... ient treated with azacitidine.

@en

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis

@nl

prefLabel

Hematologic improvements in a ...... ient treated with azacitidine.

@en

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis

@nl

P1476

Hematologic improvements in a ...... ient treated with azacitidine.

@en

P2093

Akira Matsuda

http://www.w3.org/2001/XMLSchema#string

Daisuke Okamura

http://www.w3.org/2001/XMLSchema#string

Ken Tanae

http://www.w3.org/2001/XMLSchema#string

Maho Ishikawa

http://www.w3.org/2001/XMLSchema#string

Masami Bessho

http://www.w3.org/2001/XMLSchema#string

Mika Kohri

http://www.w3.org/2001/XMLSchema#string

Naoki Takahashi

http://www.w3.org/2001/XMLSchema#string

Nobutaka Kawai

http://www.w3.org/2001/XMLSchema#string

Norio Asou

http://www.w3.org/2001/XMLSchema#string

Tomoya Maeda

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.

Thalidomide in the treatment of myelodysplastic syndrome with fibrosis.

Decitabine is an effective treatment of idiopathic myelofibrosis.

P304

24-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LRR.2014.03.002

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262150335

http://www.w3.org/2001/XMLSchema#string

P698

24809010

http://www.w3.org/2001/XMLSchema#string

P932

4009407

http://www.w3.org/2001/XMLSchema#string

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.

about

P2860

P2860

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932